title: [Value of a new induction protocol in Ewing's sarcoma. Apropos of 35 cases].
abstract: The use of a protocol of induction in Ewing's sarcoma based on the sequential association of Cyclophosphamide (150 mg/m2 for 7 days) and Adriamycin (35 mg/m2 on day 8) has shown that: 1. The clinical and radiological response (scan + MRI) even when complete is not predictive of the quality of the histological response. 2. For the histological response to be predictive, it must be evaluated on a complete monobloc resection. 3. A sustained, complete remission is more frequent after systematic extratumoral monobloc surgery and appropriate postoperative chemotherapy. When these conditions are respected, a complete remission rate of 88% at 30 months can be expected.
authors.affiliation: Unité d'Oncologie Pédiatrique, Hôpital Robert-Debré, Paris.
authors.forename: J C
authors.initials: JC
authors.lastname: Desbois
authors.forename: N
authors.initials: N
authors.lastname: Delepine
authors.forename: G
authors.initials: G
authors.lastname: Delepine
authors.forename: M
authors.initials: M
authors.lastname: Housset
authors.forename: H
authors.initials: H
authors.lastname: Cornille
authors.forename: R
authors.initials: R
authors.lastname: Favre
authors.forename: M
authors.initials: M
authors.lastname: Tubiana Hulin
authors.forename: P
authors.initials: P
authors.lastname: Touzet
authors.forename: C
authors.initials: C
authors.lastname: Jasmin
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D012512:Sarcoma, Ewing / Q000188:drug therapy*
chemical_list: D004317:Doxorubicin; D003520:Cyclophosphamide
vernacular_title: Intérêt d'un nouveau protocole d'induction dans le sarcome d'Ewing. A propos de 35 cas.